Design Therapeutics (DSGN) Projected to Release Quarterly Earnings on Thursday

Design Therapeutics (NASDAQ:DSGN) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.36) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Tuesday, April 28th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.07. On average, analysts expect Design Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Design Therapeutics Trading Up 1.3%

DSGN stock opened at $12.02 on Thursday. The company’s 50-day moving average price is $12.40 and its 200 day moving average price is $11.65. Design Therapeutics has a 52 week low of $3.76 and a 52 week high of $17.25. The company has a market cap of $750.77 million, a P/E ratio of -10.02 and a beta of 1.58.

Analysts Set New Price Targets

Several brokerages recently issued reports on DSGN. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald initiated coverage on Design Therapeutics in a research report on Tuesday, May 12th. They issued an “overweight” rating for the company. Oppenheimer lifted their price target on Design Therapeutics from $18.00 to $21.00 and gave the stock an “outperform” rating in a research note on Monday, May 4th. Piper Sandler reiterated an “overweight” rating and issued a $20.00 price objective on shares of Design Therapeutics in a research report on Wednesday, April 29th. Finally, Wall Street Zen upgraded shares of Design Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Institutional Investors Weigh In On Design Therapeutics

A number of large investors have recently bought and sold shares of DSGN. Russell Investments Group Ltd. raised its holdings in shares of Design Therapeutics by 69.6% in the third quarter. Russell Investments Group Ltd. now owns 6,377 shares of the company’s stock worth $48,000 after acquiring an additional 2,618 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Design Therapeutics during the fourth quarter valued at $67,000. Engineers Gate Manager LP purchased a new stake in Design Therapeutics during the 4th quarter worth about $131,000. Invesco Ltd. increased its position in Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock worth $48,000 after purchasing an additional 3,033 shares in the last quarter. Finally, MetLife Investment Management LLC raised its stake in Design Therapeutics by 47.8% in the 4th quarter. MetLife Investment Management LLC now owns 15,249 shares of the company’s stock valued at $143,000 after purchasing an additional 4,929 shares during the last quarter. Institutional investors and hedge funds own 56.64% of the company’s stock.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.